Martin H. Cohen
Division of Oncology Drug Products
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Rockville
USA
Name/email consistency: high
- Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Cohen, M.H., Johnson, J.R., Li, N., Chen, G., Pazdur, R. Clin. Cancer Res. (2002)
- Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Cohen, M.H., Williams, G., Johnson, J.R., Duan, J., Gobburu, J., Rahman, A., Benson, K., Leighton, J., Kim, S.K., Wood, R., Rothmann, M., Chen, G., U, K.M., Staten, A.M., Pazdur, R. Clin. Cancer Res. (2002)
- Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Cohen, M.H., Moses, M.L., Pazdur, R. Oncologist (2002)
- U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Cohen, M.H., Dagher, R., Griebel, D.J., Ibrahim, A., Martin, A., Scher, N.S., Sokol, G.H., Williams, G.A., Pazdur, R. Oncologist (2002)
- Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Cohen, M.H., Hirschfeld, S., Flamm Honig, S., Ibrahim, A., Johnson, J.R., O'Leary, J.J., White, R.M., Williams, G.A., Pazdur, R. Oncologist (2001)